Crystalline form of 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(Pyridazin-3-ylcarbamoyl-)-6 Azaspiro[2.5]octane-6-carboxylate as monoacylglyerol lipase inhibitor
Loading...
Author (Corporation)
Publication date
03.05.2023
Type of student thesis
Course of study
Type
12 - Patent
Editors
Editor (Corporation)
Supervisor
Parent work
Special issue
DOI of the original publication
Link
Related research data
Series
Series number
Volume
Issue / Number
Pages / Duration
Patent number
WO2023213854A1
Publisher / Publishing institution
World Intellectual Property Organization
Place of publication / Event location
Edition
Version
Programming language
Assignee
Lundbeck A/S
Practice partner / Client
Keywords
Subject (DDC)
Event
Exhibition start date
Exhibition end date
Conference start date
Conference end date
Date of the last check
ISBN
ISSN
Language
Created during FHNW affiliation
No
Strategic action fields FHNW
Publication status
Review
Open access category
License
Citation
Vetter, T., Wiener, J. J. M., Grice, C. A., Buzard, D. J., Cisar, J. S., Weber, O. D., Allan, A., Raffaele, N., Moody, J. V., & Shaghafi, M. B. (2023). Crystalline form of 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(Pyridazin-3-ylcarbamoyl-)-6 Azaspiro[2.5]octane-6-carboxylate as monoacylglyerol lipase inhibitor. World Intellectual Property Organization. https://irf.fhnw.ch/handle/11654/56137